Press releases
Browse Canadian-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Nucala is approved in Canada for use in adolescents and children aged 6 years and above with severe eosinophilic asthma
Nucala is approved in Canada for use in adolescents and children aged 6 years and above with severe eosinophilic asthma
-
Bora Pharmaceuticals to Acquire GSK Mississauga-based Facility
Bora Pharmaceuticals to Acquire GSK Mississauga-based Facility
-
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
-
ZEJULA – a new maintenance treatment option for Canadians living with ovarian cancer – now available in Canada
ZEJULA – a new maintenance treatment option for Canadians living with ovarian cancer – now available in Canada
-
GSK named one of Canada’s Top 100 Employers
GSK named one of Canada’s Top 100 Employers
-
GSK Partners with Save the Children to Address Mental Health Concerns of Children Affected by Cat Lake Crisis in Northern Ontario
GSK Partners with Save the Children to Address Mental Health Concerns of Children Affected by Cat Lake Crisis in Northern Ontario
-
Two new options for self-administration of NUCALA now approved in Canada making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment
NUCALA (mepolizumab) has been approved in Canada in two new formats
-
Many Canadian Adults Acknowledge the Importance of Immunization Yet Are Not Getting Vaccinated
Many Canadian Adults Acknowledge the Importance of Immunization Yet Are Not Getting Vaccinated
-
Local employee selected for charity mountain climb
Local employee selected for charity mountain climb
-
New Target for HIV Immune Therapy and Cure to be Explored by Trans-Atlantic Industry-Academia Collaboration
New Target for HIV Immune Therapy and Cure to be Explored by Trans-Atlantic Industry-Academia Collaboration
-
GSK statement on vaccine shortages
GSK statement on vaccine shortages
-
GSK’s Mississauga manufacturing operations undergoes $36 M modernization
GSK’s Mississauga manufacturing operations undergoes $36 M modernization
-
National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up
National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up
-
GSK and NEOMED call for proposals for innovative early stage human therapeutic projects in Quebec
GSK and NEOMED call for proposals for innovative early stage human therapeutic projects in Quebec
-
Quebec’s Committee on Immunization (CIQ) recommends preferential use of SHINGRIX for the prevention of shingles in adults aged 50 and up
Quebec’s Committee on Immunization (CIQ) recommends preferential use of SHINGRIX for the prevention of shingles in adults aged 50 and up
-
TRELEGY ELLIPTA approved in Canada as the first single inhaler triple therapy for the treatment of appropriate patients with COPD
TRELEGY ELLIPTA approved in Canada as the first single inhaler triple therapy for the treatment of appropriate patients with COPD
-
GSK Statement: GSK Voluntary Recall of VENTOLIN DISKUS Lot 786G in Canada
GSK Statement: GSK Voluntary Recall of VENTOLIN DISKUS Lot 786G in Canada
